IIRC Publication Highlights

Recent IIRC member publications in SCOPUS/Google Scholar top-rated journals and/or regarding clinical studies led by IIRC members (based on lists of top 20 cited scientific journals in https://scholar.google.com/citations?view_op=top_venues&hl=en&vq=med and https://www.scopus.com/sources.uri)

The Association of HLA-E Ligand and NKG2 Receptor Variation With Relapse and Mortality After Haploidentical Related Donor Transplantation. Petersdorf EW, McKallor C, Malkki M, Hsu K, He M, Spellman SR, Gooley T, Stevenson P. Transplant Cell Ther. 2025 Mar;31(3):137-156. doi: 10.1016/j.jtct.2025.01.004. Epub 2025 Jan 9.PMID: 39798802

Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma. Lee SM, Hamid O, Jotte R, Zakharia Y, Medina T, Gillespie-Twardy A, Mehmi I, Chandra S, Watson G, Ward P, Chaney M, Lu H, Berndt J, O'Connor BP, Rathi K, Shaikh E, Cowey CL. Clin Cancer Res. 2025 Mar 3;31(5):848-859. doi: 10.1158/1078-0432.CCR-24-1478.PMID: 39786430 

Sequential JAK inhibition enhances anti-tumor immunity after combined anti-PD-1 and anti-CTLA4.  Arias-Badia M, Chen P, Lwin YM, Srinath A, Lyu A, Fan Z, Kwek SS, Luong DN, Setayesh A, Sakamoto M, Clark M, Lea A, Wolters RM, Goodearl A, Harding FA, Gorman JV, Ritacco W, Fong L.  JCI Insight. 2025 Feb 27:e187921. doi: 10.1172/jci.insight.187921. Online ahead of print. PMID: 40014402

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy. Goel U, Zanwar S, Cowan AJ, Banerjee R, Khouri J, Dima D.Cancer Manag Res. 2025 Feb 19;17:357-372. doi: 10.2147/CMAR.S510408. eCollection 2025. PMID: 39990276 

Long-Term Outcomes and Quality of Life with Treosulfan-Based Conditioning in Hematological Malignancies. Mehta RS, Lee SJ, Gooley TA, Thur L, Dahlberg A, Delaney C, Gyurkocza B, Vo PT, Deeg HJ, Milano F. Blood Adv. 2025 Feb 19:bloodadvances.2024015392. doi: 10.1182/bloodadvances.2024015392. Online ahead of print. PMID: 39969207 

Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Galsky MD, Autio KA, Cabanski CR, Wentzel K, Graff JN, Friedlander TW, Howes TR, Shotts KM, Densmore J, Spasic M, Da Silva DM, Chen RO, Lata J, Skolnik J, Keler T, Yellin MJ, LaVallee TM, Fairchild J, Boffo S, O'Donnell-Tormey J, Dugan U, Bhardwaj N, Subudhi SK, Fong L. Clin Cancer Res. 2025 Feb 18. doi: 10.1158/1078-0432.CCR-24-3693. Online ahead of print. PMID: 39964352

Modulators of relapse risk in adults allografted for acute myeloid leukemia in measurable residual disease-positive remission. Gang M, Othus M, Sandmaier BM, Davis C, Basom RS, Walter RB. Bone Marrow Transplant. 2025 Feb 17. doi: 10.1038/s41409-025-02533-1. PMID: 39962220 

RNA polymerase II at histone genes predicts outcome in human cancer. Henikoff S, Zheng Y, Paranal RM, Xu Y, Greene JE, Henikoff JG, Russell ZR, Szulzewsky F, Thirimanne HN, Kugel S, Holland EC, Ahmad K. Science. 2025 Jan 2;387(6735):737-743. doi: 10.1126/science.ads2169. Epub 2025 Feb 13. PMID: 39946483

MorPhiC Consortium: towards functional characterization of all human genes. Adli M, Przybyla L, Burdett T, Burridge PW, Cacheiro P, Chang HY, Engreitz JM, Gilbert LA, Greenleaf WJ, Hsu L, Huangfu D, Hung LH, Kundaje A, Li S, Parkinson H, Qiu X, Robson P, Schürer SC, Shojaie A, Skarnes WC, Smedley D, Studer L, Sun W, Vidović D, Vierbuchen T, White BS, Yeung KY, Yue F, Zhou T; MorPhiC Consortium. Nature. 2025 Feb;638(8050):351-359. doi: 10.1038/s41586-024-08243-w. Epub 2025 Feb 12. PMID: 39939790. Review.

Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma. Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch RC, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared JA, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik AP, Hill BT, Kamdar M, Ortiz-Maldonado V, Martínez-Cibrian N, Shune L, Shadman M. Blood. 2025 Feb 12:blood.2024026831. doi: 10.1182/blood.2024026831. PMID: 39938007

Longitudinal Tear Cytokine Biomarkers: An Analysis from the Close Assessment and Testing for Chronic Graft-Versus-Host Disease (CATCH) Protocol. El Jurdi N, Hamilton BK, Pidala JA, Onstad L, Mun C, Jain S, Lee SJ. Transplant Cell Ther. 2025 Feb 7:S2666-6367(25)01009-7. doi: 10.1016/j.jtct.2025.02.004. PMID: 39923937

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after ¹⁷⁷Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes. Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT. Eur Urol Oncol. 2025 Feb 6:S2588-9311(25)00002-1. doi: 10.1016/j.euo.2025.01.002. PMID: 39920014

APMAT analysis reveals the association between CD8 T cell receptors, cognate antigen, and T cell phenotype and persistence. Xie J, Chen DG, Chour W, Ng RH, Zhang R, Yuan D, Choi J, McKasson M, Troisch P, Smith B, Jones L, Webster A, Rasheed Y, Li S, Edmark R, Hong S, Murray KM, Logue JK, Franko NM, Lausted CG, Piening B, Algren H, Wallick J, Magis AT, Watanabe K, Mease P, Greenberg PD, Chu H, Goldman JD, Su Y, Heath JR. Nat Commun. 2025 Feb 6;16(1):1402. doi: 10.1038/s41467-025-56659-3. PMID: 39915487. 

Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine. Carter JJ, Smith RA, Scherer EM, Skibinski DAG, Sankaranarayanan S, Luxembourg A, Kollmann T, Marty KD, Sadarangani M, Dobson S, Galloway DA. Vaccine. 2025 Feb 5;50:126817. doi: 10.1016/j.vaccine.2025.126817. PMID: 39914257.

Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma. Takayesu JSK, Parvathaneni U, Laramore GE, Panjwani N, Sillings J, Futran ND, Humphreys IM, Jafari A, Abuzeid WM, Barber B, Marchiano E, Lee SM, Thompson JA, Hall E, Bhatia S, Rodriguez CP, Liao JJ. Cancer Rep (Hoboken). 2025 Feb;8(2):e70111. doi: 10.1002/cnr2.70111. PMID: 39907094. 

Factors associated with early quality of life response to palliative care during hematopoietic cell transplantation. Newcomb RA, Amonoo HL, Kavanaugh AR, Wharton KC, Rowland M, Fausto J, Webb JA, Jackson V, Greer JA, Temel JS, Lark P, Rabideau DJ, O'Brien K, LeBlanc TW, Lee SJ, El-Jawahri A. Blood Adv. 2025 Feb 5:bloodadvances.2024014574. doi: 10.1182/bloodadvances.2024014574. PMID: 39908568.

A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, Plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers. Ko AH, Chao J, Noel MS, Shankaran V, Sohal D, Crow M, Oberstein PE, Scott AJ, McRee AJ, Rocha Lima CMSP, Fong L, Keenan BP, Soto M, Filbert EL, Hsu FJ, Yang X. Cancer Res Commun. 2025 Feb 5. doi: 10.1158/2767-9764.CRC-24-0513. PMID: 39907035.

Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study. Garrett N, Tapley A, Hudson A, … McElrath MJ, Kublin JG, Bekker LG, Gilbert PB, Corey L, Gray GE, Huang Y, Kotze P; CoVPN 3008 Ubuntu Study Team. EClinicalMedicine. 2025 Jan 20;80:103054. doi: 10.1016/j.eclinm.2024.103054. eCollection 2025 Feb. PMID: 39902315. PMCID: PMC11788791.

Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies. Jaeger-Ruckstuhl CA, Specht JM, Voutsinas JM, MacMillan HR, Wu QV, Muhunthan V, Berger C, Pullarkat S, Wright JH, Yeung CCS, Hyun TS, Seaton B, Aicher LD, Song X, Pierce RH, Lo Y, Cole GO, Lee SM, Newell EW, Maloney DG, Riddell SR. Clin Cancer Res. 2025 Feb 3;31(3):503-514. doi: 10.1158/1078-0432.CCR-24-2172.PMID: 39466024. 

Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study. Bhatia S, Topalian SL, Sharfman W, Meyer T, Steven N, Lao CD, Fariñas-Madrid L, Devriese LA, Moore K, Ferris RL, Honma Y, Elias I, Srirangam A, Garnett-Benson C, Lee M, Nghiem P. J Clin Oncol. 2025 Jan 31:JCO2402138. doi: 10.1200/JCO-24-02138. PMID: 39889250.

Recirculating regulatory T cells mediate thymic regeneration through amphiregulin following damage. Lemarquis AL, Kousa AI, Argyropoulos KV, Jahn L, Gipson B, Pierce J, Serrano-Marin L, Victor K, Kanno Y, Girotra NN, Andrlova H, Tsai J, Velardi E, Sharma R, Grassmann S, Ekwall O, Goldstone AB, Dudakov JA, DeWolf S, van den Brink MRM. Immunity. 2025 Jan 28:S1074-7613(25)00031-7. doi: 10.1016/j.immuni.2025.01.006. PMID: 39892391 4. 

Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML. Vo PT, Sandmaier BM, Othus M, Ali N, Rodríguez-Arbolí E, Orvain C, Davis C, Basom RS, Storb R, Walter RB. Bone Marrow Transplant. 2025 Jan 29. doi: 10.1038/s41409-025-02516-2. Online ahead of print. PMID: 39881206.

ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV. Pinto-Santini D, Jalil EM, Fernandes GT, Hilaire G, Kolevic L, Cabello R, Grinsztejn B, Pape W, Deschamps MM, House MG, Brofsky E, Sahasrabuddhe VV, Dasgupta S, Pasalar S, Madeleine MM, Carter J, Prabhu PR, Galloway D, Duerr A. BMC Cancer. 2025 Jan 27;25(1):151. doi: 10.1186/s12885-025-13551-z. PMID: 39871186. PMCID: PMC11771066.

Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203. Othus M, Garcia-Manero G, Appelbaum FR, Erba HP, Dietrich E, Raychaudhuri S, Appelbaum J, Estey E, Percival ME. Leukemia. 2025 Jan 27. doi: 10.1038/s41375-024-02512-3. Online ahead of print. PMID: 39870766. 

Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect. Reddi S, Senyshyn L, Ebadi M, Podlesny D, Minot SS, Gooley T, Kabage AJ, Hill GR, Lee SJ, Khoruts A, Rashidi A. Nat Commun. 2025 Jan 25;16(1):1034. doi: 10.1038/s41467-025-56375-y. PMID: 39863610. PMCID: PMC11762788.

ACQUIRED MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY CLL WHO PROGRESSED IN THE ALPINE STUDY. Brown JR, Li J, Eichhorst B, Lamanna N, O'Brien SM MD, Tam CS, Qiu L, Huang R, Shi Y, Idoine A, Salmi T, Cohen AC, Shadman M. Blood Adv. 2025 Jan 24:bloodadvances.2024014206. doi: 10.1182/bloodadvances.2024014206. Online ahead of print. PMID: 39853273.

Phase I study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult B-ALL patients. Gauthier J, Liang EC, Huang JJ, Kimble EL, Hirayama AV, Fiorenza S, Voutsinas JM, Wu QV, Jaeger-Ruckstuhl CA, Pender BS, Kirchmeier DR, Torkelson A, Braathen K, Basom R, Shadman M, Kopmar NE, Cassaday RD, Riddell SR, Maloney DG, Turtle CJ. Blood Adv. 2025 Jan 16:bloodadvances.2024015314. doi: 10.1182/bloodadvances.2024015314. Online ahead of print. PMID: 39820359.

The Association of HLA-E Ligand and NKG2 Receptor Variation with Relapse and Mortality after Haploidentical Related Donor Transplantation. Petersdorf EW, McKallor C, Malkki M, Hsu K, He M, Spellman SR, Gooley T, Stevenson P. Transplant Cell Ther. 2025 Jan 9:S2666-6367(25)00005-3. doi: 10.1016/j.jtct.2025.01.004. Online ahead of print. PMID: 39798802

Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Vitanza NA, Ronsley R, Choe M, … Wendler JP, Park JR, Jensen MC. Nat Med. 2025 Jan 7. doi: 10.1038/s41591-024-03451-3. Online ahead of print. PMID: 39775044

Endogenous thymic regeneration: restoring T cell production following injury. Granadier D, Acenas D 2nd, Dudakov JA. Nat Rev Immunol. 2025 Jan 6. doi: 10.1038/s41577-024-01119-0. Online ahead of print. PMID: 39762553. Review.

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Lopez J, Powles T, Braiteh F, … , Fong L, … , Sahin U, Türeci Ö, Camidge DR. Nat Med. 2025 Jan 6. doi: 10.1038/s41591-024-03334-7. Online ahead of print. PMID: 39762422.